SuperworthSolid Biosciences EPS SLDB
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$1.91
- Latest quarter, Q2 FY26
- −$0.38
- Fiscal year 2025
- −$2.02
Solid Biosciences' earnings per share was −$1.91 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.38.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.02 | n/a |
| FY2024 | −$3.04 | n/a |
| FY2023 | −$4.85 | n/a |
| FY2022 | −$10.73 | n/a |
| FY2021 | −$10.27 | n/a |
| FY2020 | −$25.95 | n/a |
| FY2019 | −$44.25 | n/a |
| FY2018 | −$33.60 | n/a |
| FY2017 | −$34.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.38 | n/a | −$1.91 | |
| Q1 FY26 | −$0.52 | n/a | −$1.95 | |
| Q4 FY25 | −$0.53 | n/a | −$2.02 | |
| Q3 FY25 | −$0.48 | n/a | −$2.49 | |
| Q2 FY25 | −$0.42 | n/a | −$2.80 | |
| Q1 FY25 | −$0.59 | n/a | −$2.99 | |
| Q4 FY24 | −$1.00 | n/a | −$3.04 | |
| Q3 FY24 | −$0.79 | n/a | −$3.05 | |
| Q2 FY24 | −$0.61 | n/a | −$3.31 | |
| Q1 FY24 | −$0.64 | n/a | −$3.95 | |
| Q4 FY23 | −$1.01 | n/a | −$4.85 | |
| Q3 FY23 | −$1.05 | n/a | −$5.16 |
Against its peers
Companies in Biotechnology nearest Solid Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SLDBSolid Biosciences | −$1.91 | |
| MGTXMeiraGTx | $0.71 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Solid Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.